SIM
KALV

Spark Investment Management’s KalVista Pharmaceuticals KALV Stock Holding History

Spark Investment Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,910
Closed -$98K – 171
2020
Q1 		$98K Buy
+12,910
New +$174K 0.05% 281
2018
Q4 		– Sell
-12,328
Closed -$272K – 731
2018
Q3 		$272K Sell
12,328
-1,072
-8% -$14.5K 0.02% 534
2018
Q2 		$108K Buy
+13,400
New +$118K 0.01% 593

Other funds holding KALV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Spark Investment Management's KALV Position: Q2 2020 in Review

Spark Investment Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2020, closing a stake of 12,910 shares — an estimated $98K sold.

Spark Investment Management first reported a position in KALV in Q2 2018 and held it in 3 quarters. The position peaked at $272K in Q3 2018. 72 funds tracked by Wall St. Rank hold KALV as of Q2 2020.

  • Spark Investment Management reported no remaining KalVista Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Spark Investment Management sold 12,910 KalVista Pharmaceuticals shares in Q2 2020, an estimated $98K.
  • Spark Investment Management first reported a position in KalVista Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Spark Investment Management's KalVista Pharmaceuticals position peaked at $272K in Q3 2018.
  • 72 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.